Internal link ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 avril 13, 2021 at 08:15 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares avril 05, 2021 at 08:15 PM UTC
Internal link ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021 avril 02, 2021 at 08:15 PM UTC
Internal link ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares mars 31, 2021 at 02:25 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares mars 30, 2021 at 08:05 PM UTC
Internal link ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials mars 24, 2021 at 11:00 AM UTC
Internal link ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome mars 17, 2021 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference mars 02, 2021 at 09:30 PM UTC
Internal link ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results février 25, 2021 at 12:00 PM UTC
Internal link ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome février 16, 2021 at 09:30 PM UTC
Internal link ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 janvier 07, 2021 at 12:00 PM UTC